A key breakthrough in understanding MGN’s pathogenesis has been the identification of autoantibodies targeting the M-type phospholipase A2 receptor (PLA2R) on podocytes. This evidence concerns the gene PLA2R1 and idiopathic membranous glomerulonephritis.